New drug targets Hard-to-Treat lung cancer mutations
NCT ID NCT07249372
First seen Jan 09, 2026 · Last updated May 25, 2026 · Updated 15 times
Summary
This study tests a new drug called DRP-104 in people with advanced non-small cell lung cancer that has specific genetic changes (NFE2L2 or KEAP1). The drug works by blocking glutamine, a nutrient cancer cells need to grow. About 37 participants will receive the drug to see if it shrinks tumors or slows cancer progression. This is for patients whose cancer has worsened after standard treatments like chemotherapy and immunotherapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Columbia University
RECRUITINGNew York, New York, 10032, United States
Contact
-
NYU Langone Health
RECRUITINGNew York, New York, 10016, United States
Conditions
Explore the condition pages connected to this study.